CAS NO: | 946414-94-4 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
25mg | 电议 |
50mg | 电议 |
生物活性 | Nivolumab is a programmed death receptor-1 (PD-1) blocking humanIgG4antibody to treat advanced (metastatic) non-small cell lungcancer. |
体外研究 (In Vitro) | Nivolumab binds to CHO cells expressing PD-1 with an EC50of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab binds to PD-1 on activated T cells with an EC50of 0.64 nM. Nivolumab also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC50values of 2.52 and 2.59 nM, respectively. Nivolumab (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus[1]. |
体内研究 (In Vivo) | Nivolumab (10 and 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 and TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab exposure increases in an approximately dose-proportional manner between 10 and 50 mg/kg, with no substantial sex differences noted[1]. |
Clinical Trial | |
分子量 | 143599.09 |
性状 | Liquid |
CAS 号 | 946414-94-4 |
中文名称 | 纳武单抗;尼鲁单抗 |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |